RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) (Restore)

• ClinicalTrials.gov Identifier: NCT02090114
• Recruitment Status: Completed
• First Posted: March 18, 2014
• Results First Posted: June 27, 2022
• Last Update Posted: June 27, 2022
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Tracking Information

• First Submitted Date: March 4, 2014
• First Posted Date: March 18, 2014
• Results First Submitted Date: April 26, 2022
• Results First Posted Date: June 27, 2022
• Last Update Posted Date: June 27, 2022
• Actual Study Start Date: August 25, 2014
• Actual Primary Completion Date: November 11, 2021 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: June 1, 2022)

• Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy (BAT) [ Time Frame: up to 18 months ]
  Number of participants with ≥50% PSA reduction from pre-BAT baseline level
• PSA Response to Enzalutamide or Abiraterone Acetate Post Bipolar Androgen Therapy [ Time Frame: up to 24 months ]
  Number of participants with ≥50% PSA reduction after enzalutamide or abiraterone acetate post-BAT from baseline

Original Primary Outcome Measures (submitted: March 14, 2014)

• PSA response to Bipolar Androgen Therapy [ Time Frame: On average at 18 months ]
  PSA response to BAT (≥50% PSA reduction from pre-BAT baseline level).
• PSA response to enzalutamide or abiraterone acetate post Bipolar Androgen Therapy [ Time Frame: On average at 24 months ]
  PSA response to enzalutamide or abiraterone acetate post-BAT (≥50% PSA reduction from baseline PSA level obtained at initiation of enzalutamide or abiraterone acetate post-BAT)

Current Secondary Outcome Measures (submitted: June 1, 2022)

• PSA Progression on Enzalutamide or Abiraterone Acetate or Castrate Levels Post-BAT [ Time Frame: up to 18 months ]
  Time to PSA progression on enzalutamide or abiraterone acetate or return to castrate levels of testosterone post-BAT, defined as the time from the date of re-initiation of enzalutamide or abiraterone acetate or castration-only therapy to the date of the PSA measurement when it shows an increase by ≥25% above the nadir value that occurred following re-initiation of enzalutamide or abiraterone acetate or castration-only therapy and confirmed by a repeat PSA 4 weeks later (PCWG2).
• PSA Progression on BAT (Bipolar Androgen Therapy ) [ Time Frame: up to 18 months ]
  Time to PSA progression on BAT. Time to PSA progression on BAT is defined as the time from the date of initial dose of Testosterone to the date of the PSA measurement when it shows an ≥25% increase above the nadir value and confirmed by a repeat PSA 4 weeks later (PCWG2 criteria) during the treatment with BAT.
• Disease Response as Defined by RECIST 1.1 (Soft Tissue Lesions) and PCWG2 Criteria (Bone Lesions) [ Time Frame: up to 18 months ]
  Number of participants with complete or partial response post-BAT as defined by RECIST 1.1 (for soft tissue lesions) and PCWG2 criteria (for bone disease), or return to castration-only post-BAT.
• Initiation of Docetaxel Chemotherapy [ Time Frame: up to 18 months ]
  Time to initiation of docetaxel chemotherapy
• Quality of Life (QoL) as Assessed by FACIT-F Score [ Time Frame: up to 18 months ]
  Functional Assessment of Chronic Illness Therapy, Fatigue Subscale (FACIT-F) assesses Fatigue with a total score range of 0-52, with a higher score reflecting better QoL.
• Safety and Tolerability as Assessed by Number of Participants With Adverse Events [ Time Frame: 18 months ]
  Number of participants who experience adverse events, as defined by NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
• Quality of Life (QoL) as Assessed by RANDSF-36 [ Time Frame: up to 18 months ]
  RAND 36-Item Short Form (RANDSF-36) assesses physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, general health perceptions, and perceived change in health with a total score range of 0-100. The total score from all of the questions answered is divided by the total number of the questions answered yielding a global score from 0-100, with a higher score reflecting a better QoL.
• Quality of Life (QoL) as Assessed by BPI [ Time Frame: up to 18 months ]
  Brief Pain Inventory (BPI) assesses the severity of pain and its impact on functioning with scales ranging from 0-10, with a higher score indicating a higher level of pain.
• Quality of Life (QoL) as Assessed by IIEF [ Time Frame: up to 18 months ]
  International Index of Erectile Function (IIEF-5) is a diagnostic tool for erectile dysfunction, with a total score range of 5-25, with the lowest score indicating a higher degree of dysfunction.
• Quality of Life (QoL) as Assessed by PANAS [ Time Frame: up to 18 months ]
  Positive and Negative Affect Schedule (PANAS) is a self-report measure that is made up of two mood scales, one measuring positive affect and the other measuring negative affect, with a total score range from 10-50 with a higher score on the positive scale indicating greater levels of positive affect and a lower score on the negative scale indicating less of a negative affect.

Original Secondary Outcome Measures (submitted: March 14, 2014)

• PSA progression on enzalutamide or abiraterone acetate post-BAT [ Time Frame: On average at 18 months ]
  Time to PSA progression on enzalutamide or abiraterone acetate post-BAT
• PSA progression on BAT (Bipolar Androgen Therapy ) [ Time Frame: On average at 18 months ]
  Time to PSA progression on BAT
• Measurable disease response [ Time Frame: On average at 18 months ]
  Measurable disease response post-BAT and post-treatment with enzalutamide or abiraterone acetate post-BAT.

  1. For soft tissue lesions, based on RECIST 1.1.
  2. For bone disease, based on PCWG2 criteria.
• initiation of docetaxel chemotherapy [ Time Frame: On average at 18 months ]
  Time to initiation of docetaxel chemotherapy
• Quality of life [ Time Frame: On average at 18 months ]
  The following quality of life surveys will be administered: FACIT-F, RANDSF-36, Brief Pain Inventory, IIEF and PANAS,
• Safety and Tolerability [ Time Frame: On average at 18 months ]
  Adverse events will be collected at each clinic visit and classified for severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
• Fasting glucose [ Time Frame: On average at 18 months ]
  Fasting blood glucose level
• hemoglobin A1c [ Time Frame: On average at 18 months ]
  hemoglobin A1c level
• Fasting insulin [ Time Frame: On average at 18 months ]
  Fasting insulin levels
• Serum N-telopeptide [ Time Frame: On average at 18 months ]
  Serum N-telopeptide levels
• Osteocalcin [ Time Frame: On average at 18 months ]
  Osteocalcin levels

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
• Official Title: A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies
• Brief Summary: Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide, abiraterone or castration-only therapy in men with metastatic CRPC who previously progressed on one of these forms of therapy. The study will enroll four cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A; n=30); men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B; n=30); men with metastatic CRPC who have progressed on first line castration-only therapy (Cohort C; n=30); men with metastatic CRPC with inactivating somatic or germline mutations in ≥2 of the genes TP53, PTEN, or RB1 (Cohort D; n=20).
• Detailed Description: The trial will enroll up to 110 patients, 30 for each Cohorts A-C and 20 for Cohort D. Eligible patients will continue on androgen ablative therapy with LHRH agonist (i.e. Zoladex, Trelstar, Eligard or Lupron) if not surgically castrated to suppress endogenous testosterone production. Patients will also receive intramuscular injection with either testosterone cypionate or testosterone enanthate at a dose of 400 mg every 28 days. This dosing scheme was designed to produce rapidly fluctuating serum testosterone levels from the supraphysiologic to the near-castrate range (i.e. Bipolar Androgen Therapy [BAT]). Assessments for response to testosterone will be made approximately every 3 months. Upon displaying evidence of progression, patients will then go on to receive either abiraterone (Cohort B) or enzalutamide (Cohort A), whichever agent they had previously progressed on prior to study enrollment. Patients in Cohort C will remain on LHRH agonist therapy and receive no additional androgen ablative hormonal therapy while those in the mutation-positive Cohort D will receive enzalutamide regardless of prior therapy.
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Non-Randomized; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Prostate Cancer

Intervention

• Drug: Testosterone cypionate
  DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
  Other Name: DEPO-Testosterone Injection
• Drug: Testosterone Enanthate
  Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
  Other Name: Delatestryl
• Drug: Abiraterone acetate
  Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
  Other Name: Zytiga
• Drug: Enzalutamide
  XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
  Other Name: Xtandi

Study Arms

• Experimental: Cohort A:Post-enzalutamide
  Men with castration-resistant prostate cancer who have progressed on enzalutamide will be enrolled to this cohort. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with enzalutamide 160 mg by mouth daily.
  Interventions:

  • Drug: Testosterone cypionate
  • Drug: Testosterone Enanthate
  • Drug: Enzalutamide
• Experimental: Cohort B: Post-abiraterone
  Men with castration-resistant prostate cancer who have progressed on abiraterone will be enrolled to this cohort. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with abiraterone 1000 mg by mouth daily.
  Interventions:

  • Drug: Testosterone cypionate
  • Drug: Testosterone Enanthate
  • Drug: Abiraterone acetate
• Experimental: Cohort C: Castration Only
  Men with metastatic prostate cancer who have only received first line hormone therapy with LHRH agonist alone or LHRH agonist plus an anti-androgen. Patients who have developed castrate resistance to first line therapy and have then received second line hormone therapy of any kind (including flutamide, bicalutamide, nilutamide, ketoconazole, abiraterone, enzalutamide, ARN-509 and investigational anti-androgens) are not eligible for enrollment in this cohort.
  Interventions:

  • Drug: Testosterone cypionate
  • Drug: Testosterone Enanthate
• Experimental: Cohort D: Mutation
  Men with metastatic prostate cancer who have castrate resistant prostate cancer with inactivating somatic or germline mutations in the genes TP53, RB1 or PTEN identified using clinical grade sequencing of tumor tissue performed by qualified laboratory. Patients must have mutations in ≥2 of these genes to be eligible. Eligible patients must have progressed on first line hormone therapy with LHRH agonist alone and must have received at least one but not more than two second generation androgen ablative therapy (i.e. Abiraterone, Enzalutamide or Apalutamide).
  Interventions:

  • Drug: Testosterone cypionate
  • Drug: Testosterone Enanthate

Publications *

• Markowski MC, Wang H, Sullivan R, Rifkind I, Sinibaldi V, Schweizer MT, Teply BA, Ngomba N, Fu W, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Luo J, Antonarakis ES, Denmeade SR. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. Eur Urol. 2021 May;79(5):692-699. doi: 10.1016/j.eururo.2020.06.042. Epub 2020 Jul 2.
• Sena LA, Wang H, Lim ScM SJ, Rifkind I, Ngomba N, Isaacs JT, Luo J, Pratz C, Sinibaldi V, Carducci MA, Paller CJ, Eisenberger MA, Markowski MC, Antonarakis ES, Denmeade SR. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. Eur J Cancer. 2021 Feb;144:302-309. doi: 10.1016/j.ejca.2020.11.043. Epub 2020 Dec 29.
• Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: June 1, 2022): 112
• Original Estimated Enrollment (submitted: March 14, 2014): 60
• Actual Study Completion Date: November 11, 2021
• Actual Primary Completion Date: November 11, 2021 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Performance status ≤2
• Age ≥18 years
• Histologically-confirmed adenocarcinoma of the prostate
• Progressing on continuous androgen ablative therapy (either surgical castration or LHRH agonist).
• Documented castrate level of serum testosterone (<50 ng/dl).
• For Cohorts A and B, patients must have progressed on prior treatment with enzalutamide or abiraterone acetate + prednisone (by PSA criteria or radiographically).
• For castration-only Cohort C, patients must have developed castrate resistant prostate cancer after progressing on first line hormone therapy with either surgical castration or LHRH agonist or LHRH agonist plus an anti-androgen.
• For Cohort D patients must have inactivating somatic or germline mutations in ≥2 of the genes TP53, PTEN, RB1
• Patients progressing on LHRH agonist plus an anti-androgen as first line therapy must be off anti-androgen for 4 weeks prior to first treatment with testosterone.
• Patients with rising PSA on two successive measurements at least two weeks apart.

• For Cohort A (enzalutamide) and Cohort B (abiraterone acetate):

  • Prior treatment with up to 2 additional second line hormone therapies, including ketoconazole is allowed.
  • Patients who have progressed on both enzalutamide and abiraterone acetate are eligible and post-BAT will be retreated with the last second line agent they had received (e.g. patient receiving abiraterone then enzalutamide would receive retreatment with enzalutamide post-BAT).
  • Patients must be withdrawn from enzalutamide or abiraterone acetate for ≥ 4 weeks and have documented PSA increase after the withdrawal period.
  • Patients receiving prednisone in conjunction with abiraterone acetate must be weaned off prednisone prior to starting BAT.

• For Cohort C (castration-only):

  • Patients must continue on castrating therapy throughout BAT treatment.
  • No prior second line hormone treatment with flutamide, bicalutamide, nilutamide, enzalutamide, abiraterone, ketoconazole, ARN-509 or other investigational androgen ablative therapies is permitted for Cohort C.

• For Cohort D (mutation cohort):

  • Patients must continue on castrating therapy throughout BAT treatment.
  • Treatment with first-generation hormonal therapy (i.e. flutamide, bicalutamide, nilutamide), is allowed
  • Patient must have received at least one and not more than two second generation hormone therapies (i.e. enzalutamide, abiraterone, apalutamide).
• For Cohorts A-D, prior docetaxel for hormone-sensitive prostate cancer is permitted if ≤ 6 doses were given in conjunction with first-line androgen deprivation therapy and >12 months since last dose of docetaxel
• For Cohort D, one line of prior chemotherapy with docetaxel or cabazitaxel for metastatic castrate resistant prostate cancer is allowed

• Acceptable liver function:

  • Bilirubin < 2.5 times institutional upper limit of normal (ULN)
  • AST (SGOT) and ALT (SGPT) < 2.5 times ULN

• Acceptable renal function:

  -- Serum creatinine < 2.5 times ULN, OR

• Acceptable hematologic status:

  • Absolute neutrophil count (ANC) ≥ 1500 cells/mm3 (1.5 ×109/L)
  • Platelet count ≥ 100,000 platelet/mm3 (100 ×109/L)
  • Hemoglobin ≥ 9 g/dL.
• At least 4 weeks since prior surgery with full recovery (no persistent toxicity ≥ Grade 1).
• Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

• Pain due to metastatic prostate cancer requiring opioid analgesics.
• >5 sites of visceral disease in lung or liver (nonspecific lung nodules ≤1 cm in diameter are permitted).
• Prior treatment with docetaxel or cabazitaxel for metastatic castration-resistant prostate cancer is prohibited.
• Prior treatment with one line of chemotherapy for metastatic castration-resistant prostate cancer is allowed for Cohort D
• Requires urinary catheterization for voiding due to obstruction secondary to prostatic enlargement thought to be due to prostate cancer or benign prostatic hyperplasia
• Evidence of disease in sites or extent that, in the opinion of the investigator, would put the patient at risk from therapy with testosterone (e.g. femoral metastases with concern over fracture risk, spinal metastases with concern over spinal cord compression, lymph node disease with concern for ureteral obstruction).
• Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study.
• Active uncontrolled infection, including known history of AIDS or hepatitis B or C.
• Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.
• Prior history of a thromboembolic event within the last two years and not currently on systemic anticoagulation.
• Hematocrit >50%, untreated severe obstructive sleep apnea, uncontrolled or poorly controlled heart failure [per Endocrine Society Clinical Practice Guidelines (67)].

Sex/Gender

• Sexes Eligible for Study: Male

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02090114
• Other Study ID Numbers: J1416; NA_00093344 ( Other Identifier: JHM IRB ); 1R01CA184012-01 ( U.S. NIH Grant/Contract )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Original Responsible Party: Same as current
• Current Study Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Original Study Sponsor: Same as current
• Collaborators: National Cancer Institute (NCI)

Investigators

• Principal Investigator: Samuel Denmeade, MD; Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center

• PRS Account: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Verification Date: June 2022